Abstract Background: Most metastatic spinal cord lesions are located either in the intradural, extramedullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the published literature. Methods: A literature review of PubMed from 1960 to 2016 was undertaken for the publications having demographic, clinical, histological, and outcome data. Results: A total of 59 relevant papers were identified, showing 128 cases of intramedullary metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedullary metastasis was 6 months. Survival improved with multimodality therapy compared to monotherapy (4 months vs. 6.3 months) (hazard ratio = 0.501; 95% confidence interval, 0.293-0.857).
Introduction
Metastatic spread of cancer to the central nervous system is common and usually causes death. Spinal metastatic disease frequently manifests as spinal cord compression, owing to the extension of growth from the vertebral column with epidural lesions, or leptomeningeal involvement with intradural, extramedullary lesions. A small fraction, however, can metastasize to the intramedullary portion of the spinal cord (ISCM) and have different clinical presentations and outcomes.
Little is known of this rare condition, but primary lung cancer is thought to be the most common malignancy to cause ISCM. In the limited literature, ISCM is believed to represent less than 5% of all spinal metastasis [1] . Spread of disease to ISCM is thought to be from direct tumor infiltration or by hematogenous spread of cancer cells. The ISCM retains the blood-brain barrier, which hinders the initial spread of metastatic disease, but also inhibits the infusion of chemotherapy along with regulatory mechanisms.
As patients are living longer and disease recurrence in the central nervous system is increasing, we sought to review the literature and analyze the clinical characteristics of ISCM.
Materials and methods
We charged three authors with reviewing Pubmed search engine using the keywords (intramedullary, metastasis, lung) independently. Results were then combined, and conflicts in interpretation were resolved by mutual discussions. The search covered articles in English literature with human subject matter from January 1960 through December 2015. Results were then reviewed to extract raw data including age, sex, presentation, time from cancer diagnosis, pathology of the lung cancer, site of spinal cord involvement, diagnostic method, cerebrospinal fluid cytology, and associated brain and/or leptomeningeal metastatic disease. The time from diagnosis of spinal metastases until death, loss of follow-up, or living at time of reporting were measured and converted to months using the following formula: 1 week = 0.23 month.
Kaplan-Meier curves and log-rank tests were used to evaluate the association between categorical variables and survival time. The univariate Cox model was used to obtain the estimated hazard ratio (HR) between two groups. SPSS version 22 (IBM Corp., Armonk, NY, USA) was used to perform statistical analysis.
Results
Out of the 133 articles returned by searching, 59 were relevant and involved lung cancer. These included 22 case series (Table 1 ) and 37 single case reports (Table 2) , with the total number of intramedullary metastatic cases being 128. Lung cancer was the primary malignancy in 56% of the reported cases in the mixed series (Table 1) .
Age and sex distributions were recorded for all the patients (n = 128) with the median age being 60 years. Men were reported with 3:1 distribution. The median time to diagnosis (n = 91) was 6 months (range, 0-49 months). Pathology of the lung primary was available for most of the cohort (n = 123), with small cell lung carcinoma (SCLC) being the primary pathology in 40.7% (n = 50) versus nonsmall cell lung carcinoma (NSCLC) with a distribution of 20.3% adenocarcinoma, and 6.3% squamous of the total reported cases. It does not appear that metastatic disease from SCLC resulted in significantly worse survival (p = 0.27).
Magnetic resonance imaging was the modality for diagnosis in 52% (n = 39), whereas computed tomography was used in 5.3% and positron emission tomography in 4%. Twentythree patients (30.7%) were diagnosed postmortem.
Regions of disease were reported in 85.9% (n = 110). The cervical region was the most common area of intramedullary metastases with 34.5% of the available data revealing involvement. Thoracic and lumbar disease consisted of approximately two-thirds of cases. Multilevel involvement was reported in 25.5% (n = 28). There was no statistically significant overall survival difference when comparing one region of involvement versus multiregional (p = 0.15).
Interestingly, leptomeningeal disease was reported in 31.3% (n = 40) of the examined cases, but when cerebrospinal fluid was measured, cytology was positive in only 11.4% out of the 44 cases. There were 42 cases with concomitant brain metastasis, which was associated with comparable survival to the ones with negative brain metastasis with an HR of 1.01 (95% confidence interval, 0.56-1.84; p = 0.956).
Treatments used were reported in 79 of the cases. Most patients received steroids for symptomatic management. Multimodality treatment of spinal metastases included radiation, intrathecal and systemic chemotherapy, and/or surgery. A higher proportion received radiation (36.7%) and multimodality treatment (43%), as compared to surgery alone (17.7%). The multimodality group had significantly better survival outcome as compared to single form of therapy, with median survival of 6.3 months versus 4 months, respectively ( Fig. 1 ; p = 0.008, HR = 0.50; 95% confidence interval, 0.29-0.86).
Discussion
We hereby collectively studied intramedullary spinal cord metastasis arising from a lung primary. Our review shows that the use of multimodality therapy with surgery, Surveillance research from the American Cancer Society for 2016 demonstrates lung cancer to be the second leading cause of new cancer cases and is a leading cause of cancer mortality, being responsible for 27% of all cancer deaths. Intramedullary spinal cord metastatic disease is a rarely studied complication of primary lung cancer and represents less than 5% of total spinal cord metastasis. We do understand that direct tumor infiltration and hematogenous spread are the two most common methods of metastasis to the spinal cord, which are the proposed methods in ISCM also. Our goal was to review cases of ISCM in order to identify imaging and/or treatment approaches to impact and potentially improve clinical practice. We included reported case studies of intramedullary metastasis from 1960 to increase the reliability of information being extracted and capture modern approaches of management. The analysis showed comparable results to previous reports of lung cancer as being the most common source of metastasis [1, 2] ; however, this could also be related to selection bias given the exclusion of published paper with no lung cancer involvement.
Prior to the introduction of advanced imaging techniques and early detection of lung cancer in the 1980s, sensorimo- tor symptoms were the predominant initial presentations of ISCM. This is evident with the trend of discovering most of the cases through postmortem examination earlier and with imaging techniques later. However, some reported cases of primary lung cancer still present with ISCM as the initial finding [3] [4] [5] . Hematogenous spread, as stated above, is a proposed mechanism for metastasis, and the rich blood supply to the cervical spinal cord is expected to be responsible for increased incidence of regional involvement [6] . However, neither the cervical region nor the extent of multiregional metastasis appeared to affect survival in our review.
Many varied imaging techniques have been used to detect ISCM; however, magnetic resonance imaging proves to be an effective diagnostic strategy. Some reports have also found positron emission tomography-computed tomography to have a role in detecting ISCM [7, 8] .
Management of ISCM continues to be variable and experimental owing to the lack of experience and clinical study. Dam-Hieu et al. [9] proposed surgical intervention to significantly affect outcome; in our analysis, however, we did not observe whether surgery, radiation, or chemotherapy alone would change or improve survival. Using the multimodality approach with more than one intervention suggests improved median survival in this population. Although the multimodality treatment approach did significantly enhance the outcome, overall median survival continues to be grim at about 4 months. Hata et al. [10] showed an unexpected response to an oral tyrosine kinase inhibitor and radiation of more than 84 months.
Data collected in this review have significant limitations as they depend on retrospective collection performed by their respective authors and lack many details that would have affected the results of this analysis. ISCM has also been an observed complication in other cancers such as breast cancer and our inclusion criteria of primary lung cancers, thus preventing a fully realized understanding of ISCM. A limited number of retrospective cases also prevent evidence-based practice and allows only observational recommendations. Despite these limitations, the review hopes to offer a comprehensive look at a poorly understood and rare metastatic process. 
